19-Aug-2026
Business Wire (Wed, 19-Aug 9:00 AM ET)
Business Wire (Tue, 18-Aug 12:40 PM ET)
Emergent BioSolutions Balances Q2 Beat With Tough Outlook
TipRanks (Mon, 17-Aug 8:12 PM ET)
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
Business Wire (Mon, 17-Aug 1:38 PM ET)
Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Mon, 17-Aug 10:09 AM ET)
Globe Newswire (Thu, 13-Aug 10:11 AM ET)
Business Wire (Wed, 12-Aug 10:17 AM ET)
PRNewswire (Tue, 11-Aug 10:07 AM ET)
PRNewswire (Mon, 10-Aug 6:19 PM ET)
Market Chameleon (Thu, 6-Aug 5:39 AM ET)
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.
As of August 19, 2026, EBS stock price climbed to $4.89 with 1,489,002 million shares trading.
EBS has a beta of 0.96, meaning it tends to be less sensitive to market movements. EBS has a correlation of 0.02 to the broad based SPY ETF.
EBS has a market cap of $253.30 million. This is considered a Small Cap stock.
Last quarter Emergent Biosolutions reported $234 million in Revenue and $.60 earnings per share. This beat revenue expectation by $55 million and exceeded earnings estimates by $.49.
In the last 3 years, EBS traded as high as $15.10 and as low as $1.42.
The top ETF exchange traded funds that EBS belongs to (by Net Assets): AVUV, VTI, XBI, IWM, VXF.
EBS has underperformed the market in the last year with a price return of -46.8% while the SPY ETF gained +21.4%. EBS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.3% and -35.1%, respectively, while the SPY returned +5.1% and -0.1%, respectively.
EBS support price is $4.50 and resistance is $4.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.